Mandate

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

July 24, 2025

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).

Vida is a global supplier of processed products from Swedish forests. The Vida group has approximately 1,600 employees and sales of SEK 12 billion and conducts operations at 24 production facilities, including 12 sawmills. AB Karl Hedin Sågverk has three sawmills in Sweden and a well-established raw materials organisation in Bergslagen. The company has approximately 220 full-time employees and sales of SEK 1.8 billion. Following the acquisition, AB Karl Hedin Sågverk will continue to operate under its current name and trademark with Fredrik Marnefeldt as CEO.

Together Vida and AB Karl Hedin Sågverk will have a turnover of approximately SEK 14 billion, 1,800 employees and a sawmill production of 3.3 million cubic metres.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Jonas Johansson, Johan Winnerblad, Egil Svensson and Olof Löfvenberg.

Read more in AB Karl Hedin's press release 

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025